DSP Healthcare IDCW Reinvest Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹100

DSP Healthcare IDCW Reinvest Direct Plan

NAV
₹27.4250
+1.09%
(3 Jul)
AUM
2,961 Cr
TER
0.62%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+18.2%
-1.1%
-1.1%
-3.6%
-3.6%
3Y
+28.0%
+40.3%
+40.3%
+41.4%
+41.4%
5Y
+24.7%
+31.9%
+31.9%
+30.3%
+30.3%
ALL
+24.6%
+12.3%
+12.3%
+17.2%
+17.2%
VOL
16.9%
20.3%
20.3%
20.3%
20.3%
TER
0.6%
0.8%
0.8%
0.9%
0.9%
AUM
₹2,961 Cr
₹5,259 Cr
₹5,259 Cr
₹1,394 Cr
₹1,394 Cr
INFO
1.46
0.60
0.60
0.84
0.84
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
DSP Healthcare IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st May
Top holdings
Cipla Ltd
8.9%
Cohance Lifesciences Ltd
8.8%
Sun Pharmaceuticals Industries Ltd
8.7%
Ipca Laboratories Ltd
8.2%
Gland Pharma Ltd
4.9%
Alembic Pharmaceuticals Ltd
4.9%
Globus Medical Inc Class A
4.6%
Laurus Labs Ltd
4.6%
Apollo Hospitals Enterprise Ltd
4.5%
Sai Life Sciences Ltd
4.1%
Top industry exposure
Healthcare
97.5%
Financial Services
1.5%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹100
Additional lumpsum
₹100
Portfolio turnover
22%
Lock-in period
-
Exit load
• 0.5% for redemption within 30 days
Fund objective
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.
Fund manager(s)
Chirag Dagli

FAQs